GPCR Stock Overview
A clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Structure Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$33.75 |
| 52 Week High | US$66.38 |
| 52 Week Low | US$26.61 |
| Beta | 0 |
| 11 Month Change | -10.86% |
| 3 Month Change | -11.49% |
| 1 Year Change | -43.34% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 29.81% |
Recent News & Updates
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Nov 25
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Oct 22We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely
Aug 11Recent updates
Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth
Nov 25Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Oct 22We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely
Aug 11Structure Therapeutics: Yet Another Potential GLP-1 Entrant
Jun 14Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape
Jun 05Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation
Mar 10Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans
Jun 29Shareholder Returns
| GPCR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.0% | 2.6% | 0.5% |
| 1Y | -43.3% | 13.1% | 30.7% |
Return vs Industry: GPCR underperformed the US Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: GPCR underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| GPCR volatility | |
|---|---|
| GPCR Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GPCR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GPCR's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 148 | Raymond Stevens | structuretx.com |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF.
Structure Therapeutics Inc. Fundamentals Summary
| GPCR fundamental statistics | |
|---|---|
| Market cap | US$1.93b |
| Earnings (TTM) | -US$110.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-17.5x
P/E RatioIs GPCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GPCR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$110.55m |
| Earnings | -US$110.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GPCR perform over the long term?
See historical performance and comparison